Company Analysis Chugai Pharmaceutical Co., Ltd.
1. Summary
Advantages
- The stock's return over the last year (14.45%) is higher than the sector average (-34.04%).
Disadvantages
- Price (21.1 $) is higher than fair price (11.35 $)
- Dividends (0%) are below the sector average (1.76%).
- Current debt level 0.6962% has increased over 5 years from 0.008%.
- The company's current efficiency (ROE=0.142%) is lower than the sector average (ROE=13.19%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Chugai Pharmaceutical Co., Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.9% | 4.6% | -1.4% |
| 90 days | -11.3% | -37.6% | 4.2% |
| 1 year | 14.5% | -34% | 23% |
CHGCY vs Sector: Chugai Pharmaceutical Co., Ltd. has outperformed the "Healthcare" sector by 48.49% over the past year.
CHGCY vs Market: Chugai Pharmaceutical Co., Ltd. has significantly underperformed the market by -8.54% over the past year.
Stable price: CHGCY is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CHGCY with weekly volatility of 0.2779% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (21.1 $) is higher than the fair price (11.35 $).
Price is higher than fair: The current price (21.1 $) is 46.2% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (13.49) is lower than that of the sector as a whole (31.48).
P/E vs Market: The company's P/E (13.49) is lower than that of the market as a whole (46.91).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.0192) is lower than that of the sector as a whole (3.36).
P/BV vs Market: The company's P/BV (0.0192) is higher than that of the market as a whole (-8.98).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (3.95) is higher than that of the sector as a whole (3.24).
P/S vs Market: The company's P/S indicator (3.95) is lower than that of the market as a whole (4.88).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-130.58) is lower than that of the sector as a whole (9.95).
EV/Ebitda vs Market: The company's EV/Ebitda (-130.58) is lower than that of the market as a whole (25.28).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -19.79% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-19.79%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-52.93%).
5.4. ROE
ROE vs Sector: The company's ROE (0.142%) is lower than that of the sector as a whole (13.19%).
ROE vs Market: The company's ROE (0.142%) is higher than that of the market as a whole (-8.22%).
5.5. ROA
ROA vs Sector: The company's ROA (0.1195%) is lower than that of the sector as a whole (6.14%).
ROA vs Market: The company's ROA (0.1195%) is lower than that of the market as a whole (4.85%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (34.85%) is higher than that of the sector as a whole (15.56%).
ROIC vs Market: The company's ROIC (34.85%) is higher than that of the market as a whole (11.03%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.76%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0% has been steadily paid over the past 7 years, DSI=0.71.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (5698.94%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
